<DOC>
	<DOCNO>NCT00810108</DOCNO>
	<brief_summary>The objective study compare pharmacokinetics lopinavir tablet administer pediatric patient either whole crushed tablet . The study randomize , open-label , crossover study pediatric subject already take lopinavir/ritonavir tablet part clinical care . THe investigator hypothesize lopinavir exposure pediatric patient low take dose tablet formulation , crush mixed pudding yogurt , compare exposure take dose tablet swallow whole .</brief_summary>
	<brief_title>Lopinavir/Ritonavir ( Kaletra ) PK Children</brief_title>
	<detailed_description>By end 2005 , approximately 2.3 million child worldwide living HIV/AIDS.1 At least 660,000 child worldwide advance HIV/AIDS dire need antiretroviral treatment . While many barrier exist scale HIV/AIDS care treatment globally , access life-saving treatment child increase . The protease inhibitor , lopinavir/ritonavir ( Kaletra® ) , recommend first-line agent World Health Organization US Department Health Human Services treatment pediatric patient resource-limited setting United States . The prescribe information state tablet may crush , break chew , manufacturer plan examine pharmacokinetics crush tablet time . The company find crushed tablet poorly absorb small pharmacokinetic study several dog . While information spread investigator word-of-mouth , information publish forum company , guidance extent decrease absorption provide . However , patient caregiver dose pediatric patient crush tablet overcome limitation oral solution . If crush tablet administration yield significantly low systemic exposure lopinavir whole tablet , patient use administration technique high risk development viral resistance treatment failure . This administration technique must study provider evidence support recommendation dose administration strategy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Documented HIV infection Taking lopinavir/ritonavir ( Kaletra ) tablets standard pediatric dos great two week Concomitant medication and/or natural product , include potentially interacting product , stable great two week expect change course study Ability understand study procedure assent participate Parental guardian consent Aged 6 17 year Acute serious medical illness infection ( judgment investigator ) require treatment and/or hospitalization within 14 day prior study entry Pregnancy Concomitant medications/natural product start within past two week and/or change course study .</criteria>
	<gender>Female</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>HIV/AIDS</keyword>
	<keyword>pediatrics</keyword>
	<keyword>resource-limited setting</keyword>
	<keyword>lopinavir</keyword>
	<keyword>ritonavir</keyword>
	<keyword>Kaletra®</keyword>
	<keyword>antiretroviral treatment</keyword>
	<keyword>crush tablet</keyword>
	<keyword>treatment experience</keyword>
</DOC>